Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.

Journal article

Using SEER-Medicare linked data we identified elderly patients diagnosed with diffuse large B-cell lymphoma (DLBCL) between January 2000 and December 2007 who received second-line outpatient chemotherapy for relapsed or refractory disease. Second-line regimens were classified into three mutually exclusive groups: aggressive, conventional, and palliative. Of the 632 (426 relapsed, 206 refractory) patients in the cohort, 27.8% received aggressive second-line therapy, 39.1% received conventional...

Expand abstract

Authors: Danese, MD; Griffiths, RI; Gleeson, ML; Dalvi, T; Li, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Taylor and Francis
• Journal: Leukemia & Lymphoma
• Volume: 58
• Issue: 5
• Pages: 1094-1104
• Publication date: 2016-09-01
• Acceptance date: 2016-08-21
• DOI: 10.1080/10428194.2016.1228924
• EISSN: 1029-2403
• ISSN: 1042-8194
• Pmid: 27659997
• Language: English
• Keywords: survival; Treatment Outcome; second-line therapy; Aged; Ambulatory Care; diffuse large B-cell lymphoma; Aged, 80 and over; Neoplasm Staging; Lymphoma, Large B-Cell, Diffuse; Female; Health Care Costs; Kaplan-Meier Estimate; Antineoplastic Combined Chemotherapy Protocols; Recurrence; Humans; Proportional Hazards Models; elderly; Comorbidity; SEER Program; Retreatment; Age Factors; Cost; Practice Patterns, Physicians'; Male; Drug Resistance, Neoplasm; Prognosis